SG11202110574SA - Anti-egfrviii antibodies and antigen-binding fragments thereof - Google Patents
Anti-egfrviii antibodies and antigen-binding fragments thereofInfo
- Publication number
- SG11202110574SA SG11202110574SA SG11202110574SA SG11202110574SA SG11202110574SA SG 11202110574S A SG11202110574S A SG 11202110574SA SG 11202110574S A SG11202110574S A SG 11202110574SA SG 11202110574S A SG11202110574S A SG 11202110574SA SG 11202110574S A SG11202110574S A SG 11202110574SA
- Authority
- SG
- Singapore
- Prior art keywords
- antigen
- binding fragments
- egfrviii antibodies
- egfrviii
- antibodies
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 239000012634 fragment Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464404—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/47—Brain; Nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962824386P | 2019-03-27 | 2019-03-27 | |
PCT/CA2020/050376 WO2020191485A1 (en) | 2019-03-27 | 2020-03-23 | Anti-egfrviii antibodies and antigen-binding fragments thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202110574SA true SG11202110574SA (en) | 2021-10-28 |
Family
ID=72609161
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202110574SA SG11202110574SA (en) | 2019-03-27 | 2020-03-23 | Anti-egfrviii antibodies and antigen-binding fragments thereof |
Country Status (15)
Country | Link |
---|---|
US (1) | US20220193132A1 (en) |
EP (1) | EP3947461A4 (en) |
JP (1) | JP2022528368A (en) |
KR (1) | KR20210148228A (en) |
CN (1) | CN113853388A (en) |
AU (1) | AU2020249296A1 (en) |
CA (1) | CA3135043A1 (en) |
CL (1) | CL2021002500A1 (en) |
CO (1) | CO2021012705A2 (en) |
EA (1) | EA202192413A1 (en) |
IL (1) | IL286690A (en) |
MX (1) | MX2021011750A (en) |
PE (1) | PE20212212A1 (en) |
SG (1) | SG11202110574SA (en) |
WO (1) | WO2020191485A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4330285A1 (en) * | 2021-04-26 | 2024-03-06 | The Walter And Eliza Hall Institute Of Medical Research | Egfrviii binding proteins |
CN117813109A (en) * | 2021-09-01 | 2024-04-02 | 生物权威(澳大利亚)有限责任公司 | Novel dysfunctional P2X 7 Conjugate(s) |
AU2021467228A1 (en) * | 2021-09-29 | 2024-04-04 | National Research Council Of Canada | Humanized anti-egfrviii antibodies and antigen-binding fragments thereof |
WO2023049985A1 (en) * | 2021-09-29 | 2023-04-06 | National Research Council Of Canada | Egfrviii-targeted compounds and uses thereof |
CN114044826B (en) * | 2021-10-12 | 2023-11-17 | 南京融捷康生物科技有限公司 | Single-domain antibody aiming at EGFRvIII, derivative protein thereof and application |
WO2024027835A1 (en) * | 2022-08-05 | 2024-02-08 | 北京鼎成肽源生物技术有限公司 | Antibody targeting egfrviii and use thereof in cell immunotherapy |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2163256E (en) * | 2001-05-11 | 2015-11-20 | Ludwig Inst For Cancer Res Ltd | Specific binding proteins and uses thereof |
CN102558352A (en) * | 2003-06-27 | 2012-07-11 | 艾默根佛蒙特有限公司 | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
BRPI0712368A2 (en) * | 2006-07-27 | 2012-06-05 | Imclone Systems Inc | method to inhibit tumor growth in a pediatric patient |
CN104212800B (en) * | 2013-05-07 | 2017-01-18 | 南方医科大学 | Nucleic acid aptamer for specific binding with human epidermal growth factor receptor type III variant and application of nucleic acid aptamer |
-
2020
- 2020-03-23 WO PCT/CA2020/050376 patent/WO2020191485A1/en unknown
- 2020-03-23 CA CA3135043A patent/CA3135043A1/en active Pending
- 2020-03-23 KR KR1020217034931A patent/KR20210148228A/en active Search and Examination
- 2020-03-23 CN CN202080037602.8A patent/CN113853388A/en active Pending
- 2020-03-23 SG SG11202110574SA patent/SG11202110574SA/en unknown
- 2020-03-23 PE PE2021001600A patent/PE20212212A1/en unknown
- 2020-03-23 EP EP20777761.6A patent/EP3947461A4/en active Pending
- 2020-03-23 AU AU2020249296A patent/AU2020249296A1/en active Pending
- 2020-03-23 MX MX2021011750A patent/MX2021011750A/en unknown
- 2020-03-23 US US17/441,708 patent/US20220193132A1/en active Pending
- 2020-03-23 EA EA202192413A patent/EA202192413A1/en unknown
- 2020-03-23 JP JP2021557417A patent/JP2022528368A/en active Pending
-
2021
- 2021-09-26 IL IL286690A patent/IL286690A/en unknown
- 2021-09-27 CO CONC2021/0012705A patent/CO2021012705A2/en unknown
- 2021-09-27 CL CL2021002500A patent/CL2021002500A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CL2021002500A1 (en) | 2022-04-08 |
IL286690A (en) | 2021-10-31 |
PE20212212A1 (en) | 2021-11-19 |
EA202192413A1 (en) | 2021-12-30 |
CN113853388A (en) | 2021-12-28 |
EP3947461A4 (en) | 2023-03-29 |
MX2021011750A (en) | 2021-12-10 |
EP3947461A1 (en) | 2022-02-09 |
CO2021012705A2 (en) | 2022-01-28 |
US20220193132A1 (en) | 2022-06-23 |
AU2020249296A1 (en) | 2021-11-11 |
WO2020191485A1 (en) | 2020-10-01 |
JP2022528368A (en) | 2022-06-10 |
CA3135043A1 (en) | 2020-10-01 |
KR20210148228A (en) | 2021-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202004494B (en) | Anti-tmprss2 antibodies and antigen-binding fragments | |
IL269593A (en) | Anti-ilt4 antibodies and antigen-binding fragments | |
HUE061425T2 (en) | Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments | |
EP3399989A4 (en) | Anti-lag3 antibodies and antigen-binding fragments | |
IL286690A (en) | Anti-egfrviii antibodies and antigen-binding fragments thereof | |
EP3882268A4 (en) | Anti-cd73 antibody, antigen-binding fragment thereof and application thereof | |
IL289585A (en) | Dll3-targeting antibodies and uses thereof | |
IL281272A (en) | Humanized anti-c5 antibodies and uses thereof | |
SG11202112112UA (en) | Anti-galectin-9 antibodies and uses thereof | |
IL287690A (en) | Anti-hvem antibodies and use thereof | |
IL289656A (en) | Anti-tigit antibodies and application thereof | |
IL291027A (en) | Anti-steap1 antibodies and uses thereof | |
IL281608A (en) | Anti-human cd45rc antibodies and uses thereof | |
EP4083069A4 (en) | Anti-ox40 antibody and use thereof | |
IL291546A (en) | Anti-kir3dl3 antibodies and uses thereof | |
IL291550A (en) | Anti-il-27 antibodies and uses thereof | |
IL277296A (en) | Anti-pfrh5 antibodies and antigen-binding fragments thereof | |
IL291280A (en) | Anti-cd371 antibodies and uses thereof | |
IL286803A (en) | Anti-tauc3 antibodies and uses thereof | |
ZA202004784B (en) | Humanized and de-immunized antibodies | |
GB201918103D0 (en) | Epitopes and antibodies | |
GB201902590D0 (en) | Antibodies and uses thereof | |
ZA202210284B (en) | Anti-trem1 antibodies and related methods | |
EP3976091A4 (en) | Anti-tem1 antibodies and antigen-binding portions thereof | |
IL288807A (en) | Anti-talen antibodies and uses thereof |